EA028164B1 - Слитые белки для облегчения отбора клеток, инфицированных рекомбинантным вирусом осповакцины с геном специфического иммуноглобулина - Google Patents

Слитые белки для облегчения отбора клеток, инфицированных рекомбинантным вирусом осповакцины с геном специфического иммуноглобулина Download PDF

Info

Publication number
EA028164B1
EA028164B1 EA201491965A EA201491965A EA028164B1 EA 028164 B1 EA028164 B1 EA 028164B1 EA 201491965 A EA201491965 A EA 201491965A EA 201491965 A EA201491965 A EA 201491965A EA 028164 B1 EA028164 B1 EA 028164B1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunoglobulin
library
antigen
virus
eeu
Prior art date
Application number
EA201491965A
Other languages
English (en)
Russian (ru)
Other versions
EA201491965A1 (ru
Inventor
Эрнест С. Смит
Трэйси Пандина
Лесли А. Крой
Марк Пэрис
Морис Заудерер
Ангелика Мокса
Рене Кирк
Original Assignee
Вэксинекс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вэксинекс, Инк. filed Critical Вэксинекс, Инк.
Publication of EA201491965A1 publication Critical patent/EA201491965A1/ru
Publication of EA028164B1 publication Critical patent/EA028164B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EA201491965A 2012-04-26 2013-04-26 Слитые белки для облегчения отбора клеток, инфицированных рекомбинантным вирусом осповакцины с геном специфического иммуноглобулина EA028164B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261639046P 2012-04-26 2012-04-26
US201261732776P 2012-12-03 2012-12-03
US13/844,388 US9708601B2 (en) 2012-04-26 2013-03-15 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
PCT/US2013/038497 WO2013163602A1 (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Publications (2)

Publication Number Publication Date
EA201491965A1 EA201491965A1 (ru) 2015-03-31
EA028164B1 true EA028164B1 (ru) 2017-10-31

Family

ID=49477810

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491965A EA028164B1 (ru) 2012-04-26 2013-04-26 Слитые белки для облегчения отбора клеток, инфицированных рекомбинантным вирусом осповакцины с геном специфического иммуноглобулина

Country Status (16)

Country Link
US (3) US9708601B2 (enExample)
EP (1) EP2841606B1 (enExample)
JP (2) JP6498599B2 (enExample)
KR (1) KR102108589B1 (enExample)
CN (1) CN104520444B (enExample)
AU (1) AU2013251371B2 (enExample)
CA (1) CA2871597C (enExample)
DK (1) DK2841606T3 (enExample)
EA (1) EA028164B1 (enExample)
ES (1) ES2725673T3 (enExample)
IL (1) IL235323B (enExample)
NZ (1) NZ630854A (enExample)
PL (1) PL2841606T3 (enExample)
PT (1) PT2841606T (enExample)
SG (1) SG11201406974YA (enExample)
WO (1) WO2013163602A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2427212T3 (pl) 2009-05-08 2018-02-28 Vaccinex, Inc. Przeciwciała anty cd-100 i sposoby ich zastosowania
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
SG10201902380SA (en) 2013-06-25 2019-04-29 Vaccinex Inc Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP3107567A4 (en) * 2014-02-19 2017-10-25 Cangene Corporation Methods of modulating an immune response
KR20170019080A (ko) 2015-08-11 2017-02-21 주식회사 엘티전자 플렉시블 사이니지 장치
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
EP4059516A1 (en) * 2016-04-22 2022-09-21 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
IL270244B2 (en) 2017-05-05 2025-01-01 Vaccinex Inc Antibody against human semaphorin 4D
IL297578A (en) * 2020-05-06 2022-12-01 Vaccinex Inc Integral membrane protein display on extracellular enveloped poxviruses
US20240148903A1 (en) * 2021-03-08 2024-05-09 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system
KR20250022808A (ko) 2022-06-10 2025-02-17 백시넥스 인코포레이티드 복합 막 항원에 특이적인 항체를 선택하는 방법
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20090304627A1 (en) * 2008-05-28 2009-12-10 Vgx Pharmaceuticals, Inc. Smallpox dna vaccine and the antigens therein that elicit an immune response
US20100081575A1 (en) * 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
ATE407206T1 (de) 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
JP2003528605A (ja) 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
CA2429544C (en) * 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002062822A2 (en) 2001-02-02 2002-08-15 University Of Rochester Methods of identifying regulator molecules
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
CA2548180C (en) 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
KR101377116B1 (ko) 2004-08-27 2014-03-24 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체
US7858599B2 (en) 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
JP5357782B2 (ja) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
AU2010203451B2 (en) 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
PL2427212T3 (pl) 2009-05-08 2018-02-28 Vaccinex, Inc. Przeciwciała anty cd-100 i sposoby ich zastosowania
WO2011110642A2 (en) * 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
SMT201900074T1 (it) * 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US8603478B2 (en) * 2010-07-06 2013-12-10 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
EP2591090A4 (en) 2010-07-07 2013-12-25 Einstein Coll Med BACTERIAL VACCINES ASSOCIATED WITH CERAMIDE GLYCOLIPIDS AND USES THEREOF
EP2611832B1 (en) 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
PT2711023T (pt) 2011-05-13 2017-10-02 Univ Nat Corp Tokyo Medical & Dental Promotor da osteogénese
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
CN104520323B (zh) 2012-03-02 2018-05-04 瓦西尼斯公司 用于治疗b细胞介导的炎性疾病的方法
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
JP6363623B2 (ja) 2013-01-31 2018-07-25 ヴァクシネックス， インコーポレイテッド 免疫グロブリンａのレベルを増大するための方法
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
SG10201902380SA (en) 2013-06-25 2019-04-29 Vaccinex Inc Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP4059516A1 (en) 2016-04-22 2022-09-21 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
WO2018156509A1 (en) 2017-02-22 2018-08-30 Vaccinex, Inc. Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
US11572408B2 (en) 2017-03-20 2023-02-07 Vaccinex, Inc. Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
IL270244B2 (en) 2017-05-05 2025-01-01 Vaccinex Inc Antibody against human semaphorin 4D

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20090304627A1 (en) * 2008-05-28 2009-12-10 Vgx Pharmaceuticals, Inc. Smallpox dna vaccine and the antigens therein that elicit an immune response
US20100081575A1 (en) * 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GALMICHE et al. "Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting," Journal of General Virology, 01 November 1997 (01.11.1997), vol. 78, pgs. 3019-3027. entire document *
SMITH et al. "Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat," Journal of General Virology, 01 June 1991 (01.06.1991), vol. 72, pgs. 1349-1376, entire document *

Also Published As

Publication number Publication date
JP2019055956A (ja) 2019-04-11
US9708601B2 (en) 2017-07-18
CA2871597A1 (en) 2013-10-31
DK2841606T3 (da) 2019-05-06
IL235323B (en) 2020-01-30
CA2871597C (en) 2021-04-20
KR102108589B1 (ko) 2020-05-07
KR20150009560A (ko) 2015-01-26
PT2841606T (pt) 2019-05-17
ES2725673T3 (es) 2019-09-26
JP2015514811A (ja) 2015-05-21
US20170306318A1 (en) 2017-10-26
US9701958B2 (en) 2017-07-11
PL2841606T3 (pl) 2019-07-31
SG11201406974YA (en) 2014-11-27
AU2013251371A1 (en) 2014-11-13
JP6498599B2 (ja) 2019-04-10
US20160152971A1 (en) 2016-06-02
IL235323A0 (en) 2014-12-31
AU2013251371B2 (en) 2018-01-04
EP2841606A4 (en) 2015-12-30
CN104520444B (zh) 2017-12-12
US20130288927A1 (en) 2013-10-31
WO2013163602A1 (en) 2013-10-31
US10662422B2 (en) 2020-05-26
EA201491965A1 (ru) 2015-03-31
NZ630854A (en) 2017-03-31
EP2841606B1 (en) 2019-01-23
EP2841606A1 (en) 2015-03-04
CN104520444A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
US10662422B2 (en) Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit
US12129291B2 (en) Anti-GPC3 antibody
Karachaliou et al. IgY technology: Methods for developing and evaluating avian immunoglobulins for the in vitro detection of biomolecules
JP6043431B2 (ja) 特異的な結合タンパク質または機能性タンパク質の遺伝子転位を利用した同定
RU2625033C2 (ru) Система индикации на основе полноразмерного антитела для эукариотических клеток и ее применение
RU2759846C2 (ru) Дисплей интегрального мембранного белка на внеклеточных оболочечных вирионах поксвируса
JP7141154B2 (ja) 抗体ライブラリーの構築方法およびその使用
CN107353340B (zh) 抗h7n9全人源单克隆抗体2l11及其制法与应用
JPH02477A (ja) 相同組換えによるキメラ抗体の製造
CN107337732B (zh) 抗h7n9全人源单克隆抗体2j17及其制法与应用
TW200907059A (en) Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells
US20220323598A1 (en) Anti-ror1 monoclonal antibody, functional fragment thereof, gene, drug delivery composition, and pharmaceutical composition
US20230060376A1 (en) B cell receptor modification in b cells
EA003637B1 (ru) Новые способы идентификации биомолекул лигандов и мишеней
Bergman et al. Preferential targeting of vesicular stomatitis virus to breast cancer cells
Moore et al. Characterisation of chikungunya virus neutralising monoclonal antibodies expressed in tobacco plants
JP2022521147A (ja) ｍＲＮＡディスプレイ抗体ライブラリー及び方法
EP2311493A1 (en) Cytotoxic composition
RU2829359C1 (ru) Универсальный интеграционный вектор SB7G_HIGH и рекомбинантная плазмида SB7G_HIGH_DEV_57, обеспечивающая синтез и секрецию рекомбинантного человеческого антитела к рецептор-связывающему домену (RBD) коронавируса SARS-CoV-2 в клетках млекопитающих и полученная с использованием универсального вектора SB7G_HIGH, и рекомбинантное моноклональное антитело DEV_K57, обладающее вируснейтрализующей активностью в отношении SARS-CoV-2
CN104507970B (zh) 通过抑制p68与钙调蛋白相互作用来预防癌症转移及抑制炎症的方法
JP2011103876A (ja) キメラ抗体の一段階作製方法
JP2015163047A (ja) タンパク質の迅速改良法

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM